Karyopharm Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Karyopharm Therapeutics
KPTI Stock  USD 0.85  0.07  8.97%   
Karyopharm Therapeutics financial statements provide useful quarterly and yearly information to potential Karyopharm Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Karyopharm Therapeutics financial statements helps investors assess Karyopharm Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Karyopharm Therapeutics' valuation are summarized below:
Gross Profit
151.9 M
Profit Margin
(0.59)
Market Capitalization
105.9 M
Enterprise Value Revenue
1.1225
Revenue
148.4 M
We have found one hundred twenty available fundamental ratios for Karyopharm Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. Traders should compare all of Karyopharm Therapeutics last-minute fundamentals against the fundamentals between 2010 and 2024 to make sure the company is sustainable this year. The Karyopharm Therapeutics' current Market Cap is estimated to increase to about 1.1 B. The Karyopharm Therapeutics' current Enterprise Value is estimated to increase to about 1.1 B

Karyopharm Therapeutics Total Revenue

153.33 Million

Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 503.5 K, Interest Expense of 25 M or Selling General Administrative of 67.5 M, as well as many indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Days Sales Outstanding of 52.74. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Karyopharm Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets238.3 M240.4 M204.1 M
Slightly volatile
Total Current Liabilities73 M69.5 M31.9 M
Slightly volatile
Property Plant And Equipment Net3 M4.9 M2.6 M
Slightly volatile
Current Deferred Revenue15.7 M28.8 M15.9 M
Slightly volatile
Accounts Payable3.5 M3.1 M3.1 M
Pretty Stable
Cash101.6 M52.2 M87.3 M
Slightly volatile
Non Current Assets Total6.2 M6.5 M18.3 M
Slightly volatile
Other Assets0.951.05.6 M
Slightly volatile
Cash And Short Term Investments201.8 M192.1 M172.9 M
Slightly volatile
Common Stock Shares Outstanding119.9 M114.2 M49.5 M
Slightly volatile
Liabilities And Stockholders Equity238.3 M240.4 M204.1 M
Slightly volatile
Non Current Liabilities Total322.5 M307.2 M138.5 M
Slightly volatile
Other Current Assets6.1 M11.8 M5.3 M
Slightly volatile
Other Stockholder Equity748.9 M1.4 B640 M
Slightly volatile
Total Liabilities395.5 M376.6 M158 M
Slightly volatile
Property Plant And Equipment Gross12 M11.4 M4.5 M
Slightly volatile
Total Current Assets215.6 M233.9 M184.7 M
Slightly volatile
Short Term Debt8.5 M6.6 M10.1 M
Very volatile
Property Plant Equipment2.2 M1.3 M1.9 M
Slightly volatile
Common Stock Total Equity14.5 K13.8 K6.4 K
Slightly volatile
Capital Surpluse824.8 M1.5 B700.2 M
Slightly volatile
Common Stock7.1 K13.8 K5.9 K
Slightly volatile
Other Liabilities260.4 M248 M78.7 M
Slightly volatile
Net Invested Capital33 M34.7 M137.1 M
Pretty Stable
Net Working Capital233.5 M164.4 M160.8 M
Slightly volatile
Short and Long Term Debt Total162.5 M177 M142.2 M
Slightly volatile
Long Term Debt Total121.2 M135.6 M109.6 M
Slightly volatile
Capital Stock9.5 K13.8 K7.4 K
Slightly volatile
Net Receivables25.8 M27 M14.3 M
Slightly volatile
Capital Lease Obligations8.7 M6.1 M13.1 M
Slightly volatile
Non Current Liabilities Other929.1 K978 K73.9 M
Slightly volatile

Karyopharm Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization503.5 K530 K1 M
Pretty Stable
Selling General Administrative67.5 M131.9 M57.8 M
Slightly volatile
Total Revenue153.3 M146 M56.6 M
Slightly volatile
Gross Profit148.1 M141.1 M55 M
Slightly volatile
Other Operating Expenses177.9 M275.6 M152.8 M
Slightly volatile
Research Development108.8 M138.8 M93.6 M
Slightly volatile
Cost Of Revenue4.7 M4.9 M41.6 M
Pretty Stable
Total Operating Expenses176.4 M270.6 M151.4 M
Slightly volatile
Non Operating Income Net Other2.1 M2.6 M1.6 M
Slightly volatile
Interest Income10.2 M9.8 M2.9 M
Slightly volatile
Tax Provision203.5 K266 K167.8 K
Slightly volatile
Reconciled Depreciation613.7 K566 K731.6 K
Very volatile

Karyopharm Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation18.8 M21.7 M16.1 M
Slightly volatile
Begin Period Cash Flow98.8 M136.9 M84.6 M
Slightly volatile
Other Cashflows From Financing Activities1.1 M1.1 M35.3 M
Very volatile
Depreciation622.5 K530 K537.5 K
Slightly volatile
Total Cash From Financing Activities1.1 M1.1 M95.6 M
Pretty Stable
End Period Cash Flow102.9 M53.2 M88.4 M
Slightly volatile
Sale Purchase Of Stock3.4 M3.6 M40.1 M
Slightly volatile
Change To Netincome22.7 M40.4 M18.7 M
Slightly volatile
Net Borrowings133.5 M150.2 M163.5 M
Slightly volatile
Issuance Of Capital Stock129.8 M154.7 M133.6 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.640.6766682
Pretty Stable
Days Sales Outstanding52.7467.389867.5947
Pretty Stable
Stock Based Compensation To Revenue0.140.148720.0514
Pretty Stable
Capex To Depreciation0.210.222.205
Slightly volatile
Inventory Turnover2.561.62415.1224
Slightly volatile
Days Of Inventory On Hand219225137
Slightly volatile
Payables Turnover1.51.582511.7002
Slightly volatile
Sales General And Administrative To Revenue0.860.903125.1696
Pretty Stable
Research And Ddevelopement To Revenue0.90.9501100
Slightly volatile
Capex To Revenue8.0E-49.0E-41.5955
Slightly volatile
Cash Per Share1.591.67615.346
Slightly volatile
Days Payables Outstanding242231120
Slightly volatile
Income Quality0.890.6480.8209
Very volatile
Current Ratio3.23.366873.5905
Pretty Stable
Receivables Turnover6.965.41635.6962
Slightly volatile
Graham Number5.515.797821.7268
Slightly volatile
Capex Per Share0.00160.00170.0714
Slightly volatile
Revenue Per Share1.341.27850.7137
Slightly volatile
Interest Debt Per Share1.461.73391.316
Slightly volatile
Debt To Assets0.380.72460.3746
Slightly volatile
Operating Cycle272292205
Slightly volatile
Days Of Payables Outstanding242231120
Slightly volatile
Ebt Per Ebit0.851.10221.035
Slightly volatile
Long Term Debt To Capitalization5.174.92381.1808
Slightly volatile
Total Debt To Capitalization4.814.58241.1329
Slightly volatile
Quick Ratio3.163.32372.9829
Pretty Stable
Net Income Per E B T0.81.00230.9879
Slightly volatile
Cash Ratio0.710.751825.4119
Pretty Stable
Days Of Inventory Outstanding219225137
Slightly volatile
Days Of Sales Outstanding52.7467.389867.5947
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.121.151.034
Slightly volatile
Fixed Asset Turnover15.6229.912518.0011
Slightly volatile
Debt Ratio0.380.72460.3746
Slightly volatile
Price Sales Ratio0.640.6766682
Pretty Stable
Asset Turnover0.640.60740.2324
Slightly volatile

Karyopharm Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.1 B1.1 B674.3 M
Slightly volatile

Karyopharm Fundamental Market Drivers

Cash And Short Term Investments192.1 M

Karyopharm Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Karyopharm Therapeutics Financial Statements

Investors use fundamental indicators, such as Karyopharm Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue28.8 M15.7 M
Total Revenue146 M153.3 M
Cost Of Revenue4.9 M4.7 M
Stock Based Compensation To Revenue 0.15  0.14 
Sales General And Administrative To Revenue 0.90  0.86 
Research And Ddevelopement To Revenue 0.95  0.90 
Revenue Per Share 1.28  1.34 
Ebit Per Revenue(0.89)(0.93)

Currently Active Assets on Macroaxis

RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
SSentinelOne
WDWalker Dunlop
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
How To Invest In Karyopharm
Details
Is Karyopharm Stock a good investment?
Details
What is Karyopharm Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
1.247
Quarterly Revenue Growth
0.077
Return On Assets
(0.34)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY